keyword
MENU ▼
Read by QxMD icon Read
search

Chemotherapy-induced nausea and vomiting

keyword
https://www.readbyqxmd.com/read/28723805/acute-pancreatitis-induced-by-etoposide-lobaplatin-combination-chemotherapy-used-for-the-treatment-of-lung-cancer-a-case-report-and-literature-review
#1
Cheng-Liang Cao, Peng-Yu Duan, Wang-Jun Zhang, Le Li, Feng-Zhi Qu, Bei Sun, Gang Wang
RATIONALE: Drug-induced pancreatitis (DIP) is a rare type of pancreatitis that is not usually observed in the clinical practice. It is generally difficult to distinguish from acute pancreatitis (AP) induced by other causes. PATIENT CONCERNS: Here, we report a 62-year-old Chinese female patient with "small cell lung cancer" as the initial presentation. Because the patient could not bear the surgical treatment, the chemotherapy composed of lobaplatin and etoposide was performed...
July 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28695171/the-effect-of-reflexology-on-chemotherapy-induced-nausea-vomiting-and-fatigue-in-breast-cancer-patients
#2
Afitap Özdelikara, Mehtap Tan
OBJECTIVE: Patients receiving chemotherapy struggle with the side effects of this treatment. These side effects obligate the patients to use not only the pharmacological methods but also non-pharmacological relaxing methods. This study was conducted to determine the effect of reflexology on chemotherapy-induced nausea, vomiting, and fatigue in breast cancer patients. METHODS: The study was conducted as a pretest-posttest experimental design. The study was conducted with sixty patients, thirty as the control and thirty as the experimental groups...
July 2017: Asia-Pacific Journal of Oncology Nursing
https://www.readbyqxmd.com/read/28694084/olanzapine-reduces-chemotherapy-induced-nausea-and-vomiting-compared-with-aprepitant-in-myeloma-patients-receiving-high-dose-melphalan-before-stem-cell-transplantation-a-retrospective-study
#3
Steven Trifilio, Colleen Welles, Kristin Seeger, Shivani Mehta, MaryAnne Fishman, Katherine McGowan, Kathryn Strejcek, Emily Eiten, Carolyn Pirotte, Elizabeth Lucier, Sean DeFrates, Jayesh Mehta
INTRODUCTION: Acute and delayed chemotherapy-induced nausea and vomiting (CINV) occurs in most patients who receive high-dose melphalan and significantly affects patients' quality of life during autologous stem cell transplantation. Faced with unsatisfactory results using an aprepitant-based regimen, an olanzapine-based regimen was initiated, with the hope of improving the incidence of acute and delayed CINV. A retrospective study was conducted to compare the effectiveness of olanzapine- versus aprepitant-based regimens for CINV prevention in adult hematopoietic stem cell recipients who received high-dose melphalan...
June 20, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28691209/efficacy-of-the-oral-neurokinin-1-receptor-antagonist-aprepitant-for-nausea-and-vomiting-induced-by-cisplatin-and-carboplatin-in-japanese-patients-with-gynecological-cancer
#4
Masae Ikeda, Masako Shida, Takeshi Hirasawa, Toshinari Muramatsu, Mikio Mikami
AIM: This study was conducted to evaluate the efficacy and the difference in effects of the oral neurokinin-1(NK-1) receptor antagonist aprepitant for chemotherapy-induced nausea/vomiting (CINV) in Japanese patients with gynecological cancer receiving highly emetogenic (cisplatin) and moderately emetogenic (carboplatin) chemotherapy. METHODS: Aprepitant was added during the second course of chemotherapy in Japanese patients with grade ≥ 2 (Common Terminology Criteria for Adverse Events, version 3...
July 10, 2017: Journal of Obstetrics and Gynaecology Research
https://www.readbyqxmd.com/read/28687576/nccn-guidelines-insights-antiemesis-version-2-2017
#5
Michael J Berger, David S Ettinger, Jonathan Aston, Sally Barbour, Jason Bergsbaken, Philip J Bierman, Debra Brandt, Dawn E Dolan, Georgiana Ellis, Eun Jeong Kim, Steve Kirkegaard, Dwight D Kloth, Ruth Lagman, Dean Lim, Charles Loprinzi, Cynthia X Ma, Victoria Maurer, Laura Boehnke Michaud, Lisle M Nabell, Kim Noonan, Eric Roeland, Hope S Rugo, Lee S Schwartzberg, Bridget Scullion, John Timoney, Barbara Todaro, Susan G Urba, Dorothy A Shead, Miranda Hughes
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Antiemesis address all aspects of management for chemotherapy-induced nausea and vomiting. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Antiemesis, specifically those regarding carboplatin, granisetron, and olanzapine.
July 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28666335/a-randomized-double-blind-placebo-controlled-multicenter-study-of-a-ginger-extract-in-the-management-of-chemotherapy-induced-nausea-and-vomiting-cinv-in-patients-receiving-high-dose-cisplatin
#6
P Bossi, D Cortinovis, S Fatigoni, M Cossu Rocca, A Fabi, P Seminara, C Ripamonti, S Alfieri, R Granata, C Bergamini, F Agustoni, P Bidoli, F Nolè, M A Pessi, F Macchi, L Michellini, F Montanaro, F Roila
Background: The activity of ginger in the management of chemotherapy-induced nausea and vomiting (CINV) has been suggested, but design inadequacies, heterogeneity of the population, small numbers and poor quality of tested products limit the possibility to offer generalizable results. Patients and methods: We conducted a randomized, double-blind, placebo-controlled, multicenter study in patients planned to receive ≥2 chemotherapy cycles with high dose (>50 mg/m 2 ) cisplatin...
June 28, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28658796/comparison-of-antiemetic-effectiveness-of-palonosetron-versus-ondansetron-in-patients-on-cancer-chemotherapy-a-prospective-observational-study-in-south-indians
#7
Abdul Aslam Parathoduvil, Asha Sisupalan, Padanayil Lekshmikutty Rema
INTRODUCTION: Chemotherapy Induced Nausea and Vomiting (CINV) is the most distressing side effect of cancer chemotherapy. It can seriously produce an impact on patient's quality of life. Prevention of CINV is far more effective than treatment of an established CINV. If the patient receives an optimal antiemetic regimen during the initial course of chemotherapy, the likelihood of developing emesis is greatly reduced. Although, all first generation 5HT3 antagonists demonstrate reasonable efficacy in preventing acute CINV, delayed CINV still remains a problem...
May 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28657219/traditional-herbal-medicine-rikkunshito-for-chemotherapy-induced-nausea-and-vomiting
#8
EDITORIAL
Ken Ichirou Morishige
No abstract text is available yet for this article.
June 5, 2017: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/28657216/additive-effect-of-rikkunshito-an-herbal-medicine-on-chemotherapy-induced-nausea-vomiting-and-anorexia-in-uterine-cervical-or-corpus-cancer-patients-treated-with-cisplatin-and-paclitaxel-results-of-a-randomized-phase-ii-study-jortc-kmp-02
#9
Shunsuke Ohnishi, Hidemichi Watari, Maki Kanno, Yoko Ohba, Satoshi Takeuchi, Tempei Miyaji, Shunsuke Oyamada, Eiji Nomura, Hidenori Kato, Toru Sugiyama, Masahiro Asaka, Noriaki Sakuragi, Takuhiro Yamaguchi, Yasuhito Uezono, Satoru Iwase
OBJECTIVE: Rikkunshito, an herbal medicine, is widely prescribed in Japan for the treatment of anorexia and functional dyspepsia, and has been reported to recover reductions in food intake caused by cisplatin. We investigated whether rikkunshito could improve chemotherapy-induced nausea and vomiting (CINV) and anorexia in patients treated with cisplatin. METHODS: Patients with uterine cervical or corpus cancer who were to receive cisplatin (50 mg/m² day 1) and paclitaxel (135 mg/m² day 0) as first-line chemotherapy were randomly assigned to the rikkunshito group receiving oral administration on days 0-13 with standard antiemetics, or the control group receiving antiemetics only...
March 17, 2017: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/28638451/antiemetic-effectiveness-and-cost-saving-of-aprepitant-plus-granisetron-is-superior-to-palonosetron-in-gastrointestinal-cancer-patients-who-received-moderately-emetogenic-chemotherapy
#10
Haruka Toda, Hitoshi Kawazoe, Akiko Yano, Yuji Yamamoto, Yuji Watanabe, Yasunori Yamamoto, Yoichi Hiasa, Yoshihiro Yakushijin, Akihiro Tanaka, Hiroaki Araki
Purpose The therapeutic benefit of a three-drug combination of antiemetics has not been established in moderately emetogenic chemotherapy (MEC). The aim of this study was to compare the antiemetic effectiveness and cost-saving of palonosetron plus dexamethasone (control group) with aprepitant, granisetron, and dexamethasone (study group) in cancer patients who received MEC. Methods We switched the standard antiemetic treatment from the control group to the study group in gastrointestinal cancer patients who received MEC after October 2015...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28636760/successful-management-of-refractory-diabetic-gastroparesis-with-long-term-aprepitant-treatment
#11
N Fountoulakis, J Dunn, S Thomas, J Karalliedde
BACKGROUND: People with gastroparesis who develop treatment-resistant (refractory) disease pose a difficult challenge, especially in the setting of end-stage renal disease (ESRD) or post pancreas transplant. Aprepitant (a neurokinin-receptor antagonist) is licensed for the short-term treatment of chemotherapy-induced nausea. There is lack of information on its long-term efficacy and safety in people with diabetic gastroparesis. CASE REPORT: Case 1 was 73-year-old man with Type 2 diabetes of 25 years' duration and ESRD requiring dialysis...
June 21, 2017: Diabetic Medicine: a Journal of the British Diabetic Association
https://www.readbyqxmd.com/read/28633504/a-phase-ii-study-of-palonosetron-aprepitant-dexamethasone-and-olanzapine-for-the-prevention-of-cisplatin-based-chemotherapy-induced-nausea-and-vomiting-in-patients-with-thoracic-malignancy
#12
Kazuhisa Nakashima, Haruyasu Murakami, Kouichi Yokoyama, Shota Omori, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Fumie Nishiyama, Mami Kikugawa, Masayo Kaneko, Yumiko Iwamoto, Satomi Koizumi, Keita Mori, Takeshi Isobe, Toshiaki Takahashi
Background: The three-drug combination of a 5-hydroxytryptamine type 3 receptor antagonist, a neurokinin 1 receptor antagonist and dexamethasone is recommended for patients receiving highly emetogenic chemotherapy. However, standard antiemetic therapy is not completely effective in all patients. Methods: We conducted an open-label, single-center, single-arm Phase II study to evaluate the efficacy of olanzapine in combination with standard antiemetic therapy in preventing chemotherapy-induced nausea and vomiting in patients with thoracic malignancy receiving their first cycle of cisplatin-based chemotherapy...
June 17, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28612633/granisetron-in-the-treatment-of-chemotherapy-induced-nausea-and-vomiting-cinv-is-there-still-a-role-after-comparison-with-palonosetron
#13
Sheila A Doggrell
Chemotherapy-induced nausea and vomiting (CINV) has a negative impact on the lives of subjects receiving chemotherapy. In 2009, the second generation 5-HT3-receptor antagonist, palonosetron, which is longer-acting than granisetron, was shown, as part of dual therapy with dexamethasone, to be superior to intravenous granisetron in the delayed phase of CINV. Area covered: In an attempt to maintain plasma levels of granisetron during the delayed phase of CINV, longer-acting preparations of granisetron have been manufactured...
July 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28595433/managing-chemotherapy-induced-nausea-and-vomiting-in-head-and-neck-cancer-patients-receiving-cisplatin-chemotherapy-with-concurrent-radiation
#14
Jordan Stinson, Kelvin Chan, Justin Lee, Ronald Chow, Paul Cheon, Angie Giotis, Mark Pasetka, Bo Angela Wan, Edward Chow, Carlo DeAngelis
BACKGROUND: The purpose was to retrospectively examine the anti-emetic regimens prescribed for prophylaxis of chemotherapy-induced nausea and vomiting (CINV) for head and neck cancer patients receiving moderate- or high-emetogenic chemotherapy (MEC/HEC) along with concurrent radiation treatment at an outpatient ambulatory care center to determine the efficacy of anti-emetics prescribed. METHODS: Consecutive patients with head and neck cancers who initiated cisplatin chemotherapy with concurrent radiation treatment between January 2013 and June 2015 were investigated...
March 21, 2017: Annals of Palliative Medicine
https://www.readbyqxmd.com/read/28581463/the-burden-of-chemotherapy-induced-nausea-and-vomiting-in-children-receiving-hematopoietic-stem-cell-transplantation-conditioning-a-prospective-study
#15
J Flank, J Sparavalo, H Vol, L Hagen, R Stuhler, D Chong, S Courtney, J J Doyle, A Gassas, T Schechter, L L Dupuis
This prospective study describes chemotherapy-induced nausea and vomiting (CINV) in children (4-18 years) receiving their first hematopoietic stem cell transplant. Emetic episodes, nausea severity (assessed using a validated, self-report nausea severity assessment tool) and antiemetic administration were documented from the start of conditioning until 24 h after the last conditioning agent was administered (acute) and for a further 7 days (delayed). Relationships between CINV control and parenteral nutrition (PN) use and acute gut GvHD (aGvHD) were explored...
June 5, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28579832/apf530-versus-ondansetron-each-in-a-guideline-recommended-three-drug-regimen-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting-due-to-anthracycline-plus-cyclophosphamide-based-highly-emetogenic-chemotherapy-regimens-a-post-hoc-subgroup-analysis
#16
Ian D Schnadig, Richy Agajanian, Christopher Dakhil, Nashat Gabrail, Jeffrey Vacirca, Charles Taylor, Sharon Wilks, Eduardo Braun, Michael C Mosier, Robert B Geller, Lee Schwartzberg, Nicholas Vogelzang
BACKGROUND: APF530, a novel extended-release granisetron injection, was superior to ondansetron in a guideline-recommended three-drug regimen in preventing delayed-phase chemotherapy-induced nausea and vomiting (CINV) among patients receiving highly emetogenic chemotherapy (HEC) in the double-blind Phase III Modified Absorption of Granisetron In the prevention of CINV (MAGIC) trial. PATIENTS AND METHODS: This MAGIC post hoc analysis evaluated CINV prevention efficacy and safety of APF530 versus ondansetron, each with fosaprepitant and dexamethasone, in patient subgroup receiving an anthracycline plus cyclophosphamide (AC) regimen...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/28569078/palonosetron-compared-with-ondansetron-in-pediatric-cancer-patients-multicycle-analysis-of-a-randomized-phase-iii-study
#17
Gábor Kovács, Antonio Wachtel, Elena Basharova, Tulla Spinelli, Pierre Nicolas, Edita Kabickova
AIM: To investigate across multiple cycles the efficacy and safety of palonosetron in the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients receiving highly or moderately emetogenic chemotherapy (HEC/MEC). PATIENTS & METHODS: Patients were randomly assigned to 10, 20 μg/kg palonosetron or 3 × 150 μg/kg ondansetron for up to four cycles of HEC/MEC. RESULTS: In all on-study chemotherapy cycles, complete response rates were higher in patients in the 20 μg/kg palonosetron group than the ondansetron group...
June 1, 2017: Future Oncology
https://www.readbyqxmd.com/read/28503222/olanzapine-for-chemotherapy-induced-nausea-and-vomiting-systematic-review-and-meta-analysis
#18
Legese Chelkeba, Kidu Gidey, Ayele Mamo, Berhane Yohannes, Tsehay Matso, Tsegaye Melaku
BACKGROUND: Chemotherapy induced nausea and vomiting (CINV) remains the most distressing event in patients receiving highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC). OBJECTIVE: Therefore, this meta-analysis was conducted to evaluate the efficacy of olanzapine containing regimen in preventing acute, delayed and overall phases of CINV. METHODS: PubMed, EBSCO, and Cochrane central register of controlled trials electronic databases were searched to identify RCTs that compared the effects of olanzapine with non-olanzapine regimen in preventing CINV...
January 2017: Pharmacy Practice
https://www.readbyqxmd.com/read/28500750/nausea-and-vomiting-in-children-and-adolescents-receiving-intrathecal-methotrexate-a-prospective-observational-study
#19
Jacqueline Flank, Komail Nadeem, Sheliza Moledina, Mila Khanna, Christina Schindera, Angela Punnett, L Lee Dupuis
BACKGROUND: The prevalence of nausea and vomiting after receipt of intrathecal methotrexate (IT-MTX) in pediatric oncology patients is unknown. METHODS: Patients (4-18 years) about to receive IT-MTX were eligible to participate in this prospective, observational study. Patients received antiemetics as prescribed by their clinical team. Nausea severity (patient-assessed), timing of emetic episodes, and administration of antiemetics were recorded beginning immediately prior to IT-MTX administration, for the next 24 hr (acute phase), and for a maximum of 7 additional days (delayed phase)...
May 13, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28486012/adherence-to-and-implementation-of-asco-antiemetic-guidelines-in-routine-practice-in-a-tertiary-cancer-center-in-india
#20
Vijay M Patil, Vanita Noronha, Amit Joshi, Anant Ramaswamy, Sudeep Gupta, Arvind Sahu, Vipul Doshi, Tarachand Gupta, Sushmita Rath, Shripad Banavali, Kumar Prabhash
BACKGROUND: Nonadherence of antiemetic prescriptions to evidence-based antiemetic guidelines is associated with an increased proportion of chemotherapy-induced nausea and vomiting. The current project was carried out to improve the quality of antiemetic prescriptions at our institute. METHODS: We initially performed a retrospective analysis of 1,211 consecutive antiemetic prescription records of adult patients with solid tumors who received outpatient chemotherapy regimens...
June 2017: Journal of Oncology Practice
keyword
keyword
98586
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"